LPL Financial LLC grew its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,464,908 shares of the company’s stock after acquiring an additional 157,719 shares during the quarter. LPL Financial LLC owned approximately 0.09% of Johnson & Johnson worth $435,426,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in JNJ. Veracity Capital LLC boosted its position in Johnson & Johnson by 1.2% in the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after buying an additional 59 shares during the period. Sandy Cove Advisors LLC boosted its position in Johnson & Johnson by 1.6% in the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after buying an additional 60 shares during the period. LCM Capital Management Inc boosted its position in Johnson & Johnson by 0.7% in the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after buying an additional 61 shares during the period. Arbor Investment Advisors LLC boosted its position in Johnson & Johnson by 2.3% in the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after buying an additional 61 shares during the period. Finally, Magnolia Capital Advisors LLC boosted its position in Johnson & Johnson by 0.7% in the 3rd quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock valued at $1,451,000 after buying an additional 62 shares during the period. 67.94% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by insiders.
Analyst Ratings Changes
Johnson & Johnson Stock Down 0.2 %
NYSE:JNJ opened at $162.31 on Tuesday. The firm has a market capitalization of $421.80 billion, a P/E ratio of 33.96, a PEG ratio of 2.78 and a beta of 0.53. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $183.35. The company’s fifty day moving average price is $158.46 and its 200-day moving average price is $166.96. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.77.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.67 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. Johnson & Johnson’s dividend payout ratio is 99.58%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are Buying
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.